智通财经APP获悉，科济药业-B(02171)午后涨近7%，截至发稿，涨6.73%，报13.32港元，成交额5454.83万港元。
消息面上，科济药业近日公布2024年业绩，收益约为人民币3940万元；净亏损约7.98亿元，同比扩大6.73%。据悉，收益主要来自CAR-T细胞疗法泽沃基奥仑赛注射液（商品名：赛恺泽）。此外，3月18日，北京神农投资管理股份有限公司增持科济药业2863.15万股H股股份，价值约2.57亿港元，持股比例由4.91%升至5.01%。
西南证券指出，核心品种赛恺泽于2024年3月1日获批上市，截至12月末累计从华东医药获得154份订单。CT041用于GC/GEJ的确证性Ⅱ期临床试验达到主要终点，公司计划于2025年上半年向NMPA提交CT041的NDA。通用型CAR-T产品布局愈发完善。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.